We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GLRE:NASDAQGreenlight Reinsurance, Ltd. Analysis

Data as of 2026-09-30 - not real-time

$14.75

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

At $14.75, Greenlight Capital Re, Ltd. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Over a rolling month the price has lost 4.2%. With RSI at 33.3 the momentum picture is approaching oversold, alongside a bullish MACD signal. Price has been bracketed by support at $14.65 and resistance at $15.66.
Multiples put this in undervalued territory: 10.0 times earnings against the sector's 15.3. Revenue is contracting at 10.3% on a 7.4% profit margin.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 14.2%, a beta of -0.12 and a maximum drawdown of 22.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 4/10 conviction on the long call.

Top Market Events

GRAND CAYMAN, Cayman Islands, Aug. 04, 2026 GLOBE NEWSWIRE -- Greenlight Capital Re, Ltd. NASDAQ: GLRE "Greenlight Re"...Despite a challenging quarter marked by investment losses and conflict-related reserves, GLRE's innovation segment...GRAND CAYMAN, Cayman Islands, Sept. 01, 2026 GLOBE NEWSWIRE -- Greenlight Capital Re, Ltd. Nasdaq: GLRE "Greenlight Re"...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 15.76
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 10.0 versus sector average of 15.3
  • Trading below the 200-day average of 15.76

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 10.0 versus sector average of 15.3
  • Revenue contracting at -10.3%
  • Price-to-book of 0.70

Key Metrics & Analysis

Financial Health

Revenue Growth-10.30%
Profit Margin7.38%
P/E Ratio10.0
ROE7.50%
ROA1.78%
Debt/Equity1.66
P/B Ratio0.7
Op. Cash Flow$200.1M
Free Cash Flow$234.4M
Industry P/E15.3

Technical Analysis

TrendBearish
RSI33.3
Support$14.65
Resistance$15.66
MA 20$15.07
MA 50$15.60
MA 200$15.76
MACDBullish
VolumeIncreasing
Fear & Greed Index92.91

Valuation

Fair Value$86.05
GradeUndervalued
TypeValue

Risk Assessment

Beta-0.12
Volatility14.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.